Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study
By
LiYing Guo
Jinshuo Wang
Dongjie Du
April 30, 2026
Clinical Report: Safety and Effectiveness of Deep Hyperthermia in NSCLC
Overview {'add': "Specify the control group's treatment details."}
Background {'add': 'Include recent statistics on NSCLC treatment outcomes.'}
Data Highlights {'format': 'Ensure table format is consistent and add a footnote for statistical significance.'}
Key Findings {'add': 'Provide context for median PFS and OS results.'}
Clinical Implications {'add': 'Suggest specific future research directions.'}
Conclusion {'add': 'Reiterate the need for larger studies.'}
References
Jianming Xu, MD, The ASCO Post, 2023 -- Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma Chen et al, The ASCO Post, 2026 -- Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer Yang et al, The ASCO Post, 2026 -- Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer ASCO, Guideline Central, 2025 -- ASCO Stage IV Non-Small Cell Lung Cancer without Driver Alterations Guideline Summary Tislelizumab plus chemotherapy versus chemotherapy alone, PMC -- RATIONALE-307 trial The ASCO Post — Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer ASCO Stage IV Non-Small Cell Lung Cancer without Driver Alterations Guideline Summary Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial - PMC
